{"slug":"vip-muscle-loss","verification":{"valid":true,"entries":1,"head":"ab3c7fcfa3c02e16ee2de137171e857d44cceeafae49b734f25be3c8d114cc04"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.025469,"waste_cost_usd":0,"total_tokens":17557,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.025469,"tokens_total":17557,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:28:05.298Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide","register":"source_ledger","body":"## What's breaking down\nMuscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes protein breakdown via pathways like MuRF1, and impaired blood flow or oxygenation that limits nutrient delivery and waste removal. In disuse or ischemia models, contractile force drops as muscle fibers shrink. VIP sits in the immune and autonomic layer because it modulates inflammation and smooth muscle tone in vessels, potentially supporting repair signals rather than suppressing symptoms directly.\n\n## Why VIP might help you\nIf your muscle loss involves an immune or autonomic component, such as chronic low-grade inflammation accelerating protein breakdown or autonomic imbalance affecting blood flow, VIP is discussed for its studied effects on tissue repair pathways. Step one: VIP activates VPAC2 receptors, which in lab models reduced skeletal muscle mass loss during disuse. Step two: This receptor activation preserved force generation, pointing to a direct influence on muscle maintenance rather than masking fatigue. Step three: In reperfusion settings after ischemia, VIP raised contractile force and tissue oxygen levels above baseline in rat muscle. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. If autonomic regulation of blood vessels limits delivery during recovery, VIP's vasodilatory actions could fit there too.\n\n## How these fit together\nSingle-compound focus — VIP targets the immune/autonomic layer. If your profile includes other degeneration layers like mitochondrial decline or hormonal shifts, this peptide addresses only the immune/autonomic slice without overlapping other mechanisms.\n\n## What the evidence actually shows\nA 2005 study activated VPAC2 receptors with VIP agonists in rodent disuse models and found reduced loss of skeletal muscle mass and force (preclinical). A 1997 rat study on ischemic-reperfused skeletal muscle showed VIP given at reperfusion onset increased contractile force and oxygenation beyond baseline levels (preclinical, animal). VIP knockout mice displayed lower body weight, lower fat mass, and higher lean mass percentage compared to wild-type (preclinical). No human clinical trials specifically testing VIP administration for muscle loss or sarcopenia appear in available records. All direct muscle-related data remain at the animal level.\n\n## What scientists say\nResearchers note VPAC2 activation as a potential brake on disuse atrophy in skeletal muscle, based on the 2005 receptor study. Broader VIP reviews highlight its roles in smooth muscle relaxation, anti-inflammatory signaling, and tissue perfusion, but muscle-specific applications stay limited to preclinical observations. Human data on VIP focus more on gut motility, immune modulation in inflammatory conditions, and cardiovascular effects rather than sarcopenia.\n\n## What people say on Reddit\nAnecdotal reports mention VIP in contexts of chronic inflammation, ME/CFS recovery, or training pumps via vasodilation, with some users pairing it with other compounds for muscle-related fatigue or recovery. Posts note patience required for effects and discuss it alongside immune or gut issues rather than direct muscle building. No widespread claims of dramatic muscle gain from VIP alone surface in searches; discussions remain exploratory and tied to broader health stacks.\n\n## What people say on X\nPublic posts on X show minimal specific discussion of VIP for muscle loss. Scattered mentions cover its general vasodilatory or anti-inflammatory properties, but no detailed user experiences or before-after reports tied to sarcopenia or atrophy appear in recent searches.\n\n## What we do not know\nHuman trials measuring muscle mass, strength, or function after VIP administration are absent. Long-term effects on lean mass preservation, optimal delivery methods, and interactions with exercise or nutrition remain untested in people. Whether VIP deficiency or excess correlates with sarcopenia progression in humans is unknown. Translation from rat disuse or ischemia models to human age-related or disease-driven muscle loss has not been validated.\n\n## Safety and limits\nVIP research in humans centers on its endogenous roles and short-term physiological effects; no dedicated safety database for repeated use in muscle loss contexts exists. Animal data show receptor-specific actions without broad toxicity signals in the cited studies, but individual responses vary. Evidence grading places all muscle-related findings in the preclinical tier, with anecdotal reports at the lowest tier. Always consult primary sources and professionals for personal decisions.","claims":[{"id":"c1","text":"Activation of VPAC2 receptors with VIP agonists reduced loss of skeletal muscle mass and force in rodent disuse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Direct link to muscle preservation mechanism in lab setting.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP administration at reperfusion onset increased contractile force and tissue oxygenation in ischemic-reperfused rat skeletal muscle.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Shows potential repair support in ischemia model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP knockout mice had lower body weight, lower fat mass, and increased lean mass percentage.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates endogenous VIP role in body composition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human clinical trials test VIP for muscle loss or sarcopenia.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users discuss VIP anecdotally for inflammation recovery or training pumps but not direct muscle gain.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15649881/","title":"Activation of the vasoactive intestinal peptide 2 receptor modulates skeletal muscle mass and force","quote":"activation of VPAC2R, but not VPAC1R, reduced the loss of skeletal muscle mass and force during conditions of skeletal muscle disuse","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/9149300/","title":"Ischemic-reperfused rat skeletal muscle: the effect of vasoactive intestinal peptide","quote":"VIP administration at the onset of reperfusion significantly increased skeletal muscle contractile force and tissue oxygenation even higher than baseline","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27535909/","title":"Vasoactive intestinal peptide-deficient mice show altered body composition","quote":"VIP−/− mice showed a lower body weight and fat mass and an increased lean mass","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/","title":"Recent advances in vasoactive intestinal peptide physiology","quote":"VIP has multiple physiological and pathological effects","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"Mold illness and chronic inflammation does not get the same hype as fat loss or muscle growth. Two, VIP requires patience.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14739,"tokens_out":2818,"cost":0.02546875,"prev_hash":"genesis","hash":"ab3c7fcfa3c02e16ee2de137171e857d44cceeafae49b734f25be3c8d114cc04"}]}